Cullinan Oncology LLC (CGEM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $667.39M
Last updated: Nov 17, 2026 at 11:05 AM ET
Cullinan Oncology LLC (CGEM) Stock Forecast
Analysts expect Cullinan Oncology LLC (CGEM) to earn -$3.13 per share in the fiscal year ending Dec 31, 2026, on revenue of $13.88M. Of 12 analysts, 12 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.92, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 8.3% |
| Buy | 11 | 91.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 344.7%.
- Fiscal year ending Dec 31, 2026
- -$3.13
- EPS consensus, revenue $13.88M
- Fiscal year ending Dec 31, 2027
- -$2.47
- EPS consensus, revenue $61.72M
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.13 | -$3.79 to -$1.85 | 9 | $13.88M | N/A | 10 |
| Dec 31, 2027 | -$2.47 | -$3.93 to -$1.25 | 9 | $61.72M | N/A | 12 |
Quarterly Estimates
The EPS consensus rises from -$0.84 for the quarter ending Dec 31, 2026 to -$0.59 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.84 | -$1.14 to -$0.38 | 15 | $15.43M | N/A | 13 |
| Mar 31, 2027 | -$0.59 | -$0.99 to -$0.35 | 3 | $20.33M | N/A | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.97.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.13 | -$3.13 | -$3.13 | -$3.17 | -$2.97 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.47 | -$2.47 | -$2.52 | -$2.71 | -$2.51 | N/A |
| Quarter ending Mar 31, 2027 | -$0.59 | -$0.76 | -$0.83 | -$0.86 | -$0.86 | N/A |
Frequently Asked Questions About CGEM
What is the CGEM stock forecast?
Consensus analyst estimates put Cullinan Oncology LLC's EPS at -$3.13 for the fiscal year ending Dec 31, 2026, on revenue of $13.88M. The consensus rating from 12 analysts is Buy.
How do analysts rate CGEM stock?
Of 12 analysts covering Cullinan Oncology LLC, 1 rates it Strong Buy, 11 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CGEM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.13, with estimates from -$3.79 to -$1.85 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.47, with estimates from -$3.93 to -$1.25 from 9 analysts.
What revenue do analysts expect from Cullinan Oncology LLC next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $13.88M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $61.72M.
How many analysts cover CGEM?
12 analysts rate Cullinan Oncology LLC stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CGEM pages: Overview, Earnings, Forecast, Financials, Competitors